Neuro-Hitech, Inc. Announces Completion of Double-Blind Part of Phase Two Clinical Trial of Huperzine A in Alzheimer's Disease

NEW YORK--(BUSINESS WIRE)--Neuro-Hitech, Inc. (NASDAQ: NHPI), a New York-based biopharmaceutical company focused on developing innovative drugs for the treatment of neurodegenerative diseases, today announced the completion of the double-blind part of its Phase 2 clinical trial of Huperzine A in the treatment of patients with mild to moderate Alzheimer’s disease (AD).

Back to news